Key facts
- Kincell Bio’s last known valuation is $66.0M (Jul 2023).
- It has raised $58.0M; the latest was Early Stage VC ($22.0M) in May 2025.
- Notable investors include NewSpring Capital, Kineticos Life Sciences Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Kincell Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Kincell Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kincell Bio
Operator of a contract development and manufacturing organization intended to advance autologous and allogeneic cell therapies for patients. The company streamlines CMC development, applying expertise in analytical and processing development and GMP manufacturing to test and release from early clinical to pivotal studies and product launch, enabling researchers and laboratories to process development and manufacturing from early clinical to pivotal supply and commercial launch, ensuring rapid timelines without compromising on quality.
- Sector
- Healthcare
- HQ
- Gainesville, FL, United States
- Founded
- 2023
- Employees
- 82
- Website
- kincellbio.com/
- Ownership
- Privately Held (backing)
Kincell Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kincell Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kincell Bio in its N-PORT filings yet. We sweep new filings monthly.